PHAR (Pharming Group N.V.) חוב לטווח קצר להון

Pharming Group N.V. (PHAR) generates revenue through the sale of patented biologics for the treatment of hereditary angioedema via insurance reimbursements. This price action chart on GURU.Markets shows that the indicator is 0.01. Price stability is underpinned by a staff of leading Western scientists, which eliminates any talent shortage. In the long term, growth is supported by a strategic focus on protein bioengineering and the therapy of orphan diseases.

Pharming Group N.V. maintains a monopoly position in the orphan drug segment, where its unique biotechnologies generate a steady cash flow that minimizes reliance on external borrowing. By analyzing the short-term debt to equity ratio, investors assess the relationship between short-term liabilities and equity, allowing them to identify liquidity risks or excessive resource management conservatism through the extremes on the chart.